{"schema":"hottub-news/story/v1","story":"st_72cxtp2ly7uogdwtdisq","title":"タグリッソの重大な副作用に「再生不良性貧血」追加","title_en":null,"outlets":1,"brief":null,"page":"https://hottub.news/stories/story-72cxtp2ly7","count":1,"items":[{"id":"n_72cxtp2ly7uogdwtdisq","seq":842178,"kind":"article","title":"タグリッソの重大な副作用に「再生不良性貧血」追加","url":"https://medical-tribune.co.jp/news/articles?blogid=7&entryid=616448","summary":"厚生労働省は昨日（9月29日）付で医薬局医薬安全対策課長通知（医薬安発0929第1号）を発出。「重大な副作用」の項に①第三世代EGFRチロシンキナーゼ阻害薬（EGFR-TKI）のオシメルチニブ（商品名タグリッソ）は「再生不良性貧血」を、②複数の免疫チェックポイント阻害薬（ICI）は「重度の胃炎、食道炎」を、③インターロイキン（IL）-6阻害薬のトシリズマブ（アクテムラ他）は「薬剤性過敏症症候群」を...","published":"2026-09-30T07:02:54Z","seen":"2026-09-30T07:02:54Z","lang":"en","source":{"id":"kite-medical-tribune-co-jp-14fcf3","name":"medical-tribune.co.jp","domain":"medical-tribune.co.jp"},"via":"kite-medical-tribune-co-jp-14fcf3","topics":["medicine","@mtn（読売）,@mtn（j&j）,@mtn（武田薬品工業）,@提供記事,整…"],"entities":[{"id":"Q29006526","name":"Tagrisso","type":"other"}],"image":"https://asset.mtweb.jp/media/2026/06/02185852/25_Tenbunkaitei.jpg","story":"st_72cxtp2ly7uogdwtdisq","category":"health","category_p":0.8399999737739563,"sentiment":"negative","tone":-0.8199999928474426,"political":0.09000000357627869}]}